Bacteriophage Therapy Market (Phage Therapy Market; Virus: Campylobacter, Salmonella, Escherichia coli, Listeria, Klebsiella, and Staphylococcus spp., Key Players: Armata Pharmaceuticals, Inc, Micreos, TechnoPhage) Industry Scenario, Market Size, Outlook, Trend and Forecast 2019 – 2030

The Global Bacteriophage Therapy Market is expected to foresee a compound annual growth rate of 8.1% from 2021 to 2030.

Bacteriophage Therapy Market

Phage therapy or bacteriophage therapy uses viruses to treat pathogenic infections. A virus is also known as phages or bacteria eaters. In phage therapy, the virus only attacks the bacteria and is harmless to the host human, plant, or animals. In simple terms, bacteriophages are the natural enemies of bacteria and the virus kills the target bacteria by injecting its genes into the DNA or RNA of the bacteria, causing no harm to other bacteria. Bacteriophages are the most common biological entities of nature and are quite efficient at fighting & destroying drug-resistant bacteria.

Human Phage Therapy Diseases and Bacteria by Region

Increasing antimicrobial & antibiotic resistance globally, hike in the application of phage therapy among industries such as the food & beverage industry, upsurge in the foodborne diseases globally, and the ongoing extensive R&D are driving the global market of phage therapy. However, phage therapy is still under clinical trials, significant risk of product failure, and company pipelines coupled with the absence of skilled experts, specialists, and professionals are thereby hampering the market growth. In addition, the high cost of bacteriophage therapy is also one of the major factors limiting the worldwide bacteriophage therapy market's growth.

  • Currently, bacteriophage therapy is undergoing clinical trials for the treatment of diseases such as Urinary Tract Infection Bacterial, HIV Infection, Prostate Cancer, Acute Tonsillitis, Primary Immune Deficiency Diseases, Wound Infections, Mild Gastrointestinal, Venous Leg Ulcers, Covid19, Tuberculosis, Cystic Fibrosis, Bacterial Infections, and others, thereby paving ways for phage therapy to replace antibiotics in upcoming years.
  • WHO states that almost 420,000 die every year due to food-borne diseases, and approx. 600 million people (almost 1 in 10 people) fall sick as a result of contaminated food globally.
  • Bacteriophages are proving to be a new frontier in molecular biology owing to their efficiency in treating targeted pathogens without causing much harm to other cells.
  • In 2019, FDA accepted the New Drug Application presented by the physician-scientists of the University of California San Diego School of Medicine who collaborated with AmpliPhi Biosciences Corporation, a biotechnology company, and conducted the first U.S. clinical trial of intravenous bacteriophage-based therapy.

By Region, the global bacteriophage therapy market is segmented into North America, Latin America, Europe, Asia Pacific, and the Rest of the World. Among all the geographies, North America is dominating the market in terms of share owing to factors such as early adoption of new & emerging technologies coupled with expanding volumes of data. However, Asia Pacific is anticipated to witness the highest CAGR During forecast period owing to the increasing patient population and government initiatives to boost the healthcare sector in the region.

The prominent players inducing the Global Bacteriophage Therapy Market are SNIPR BIOME, Armata Pharmaceuticals, Inc. Adaptive Phage Therapeutics, Phagelux, Microgen Russia, BiomX (MBcure Ltd.), Enbiotix, Eligo Bioscience, MicroPhage Inc., Phage International, Intralytix, Inc, InnoPhage, Locus Biosciences, Bitbiome, and PhagoMed Biopharma GmbH, among others.

 Europe Bacteriophage Market

Segmentation and Scope of the Global Bacteriophage Therapy Market

Global Bacteriophage Therapy Market is segmented by type, target, base, route of administration, application, distribution channel, end-user, and region.

By Type

  • Lysogenic
  • Lytic

By Target

  • Staphylococcus
  • Pseudomonas
  • Escherichia Coli
  • Streptococcus
  • Salmonella
  • Others

By Base

  • Water-soluble Jelly
  • Sterile Broth Culture

By Route of Administration

  • Parenteral
  • Dermal
  • Oral
  • Rectal
  • Others

By Application

  • Infections of the Skin & Nasal Mucosa
  • Lung & Pleural Infections
  • Bacterial Dysentery
  • Supportive Skin Infection
  • Postoperative Wound Infections
  • Others

By Distribution Channel

  • Third Party Distributors
  • Direct Sales

By End-User

  • Specialty Clinics
  • Hospitals
  • Academic Research and Institutes
  • Others

By Region

North America

  • US
  • Canada
  • Mexico

Europe

  • UK
  • Germany
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • India
  • China
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific

Rest of World

Middle East & Africa

  • Saudi Arabia
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Argentina
  • Brazil
  • Rest of Latin America

Bacteriophage Therapy Market

Prominent players in the Global Bacteriophage Therapy Market among other includes

  • SNIPR BIOME
  • Armata Pharmaceuticals Inc.
  • Adaptive Phage Therapeutics
  • Phagelux
  • Microgen
  • BiomX (MBcure Ltd.)
  • Enbiotix
  • Eligo Bioscience
  • MicroPhage Inc.
  • Phage International Inc.
  • Intralytix Inc.
  • InnoPhage
  • Locus Biosciences
  • Bitbiome
  • PhagoMed Biopharma GmbH
Back to top

Payment Options

Single User $3746.25
$4995
Five User $3881.25
$ 5175
Enterprise $6881.25
$ 9175
Datapack $974.25
$ 1299
Short Report: $1349.25
$ 1799